See more : Stream Ideas Group Limited (8401.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Perpetua Resources Corp. (PPTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Perpetua Resources Corp., a leading company in the Other Precious Metals industry within the Basic Materials sector.
You may be interested
- OneLogix Group Limited (OLG.JO) Income Statement Analysis – Financial Results
- Meghmani Finechem Limited (MFL.NS) Income Statement Analysis – Financial Results
- V-cube, Inc. (VCCBF) Income Statement Analysis – Financial Results
- Nouveau Global Ventures Limited (NOUVEAU.BO) Income Statement Analysis – Financial Results
- IQGeo Group plc (IQG.L) Income Statement Analysis – Financial Results
Perpetua Resources Corp. (PPTA)
About Perpetua Resources Corp.
Perpetua Resources Corp. engages in the mineral exploration activities in the United States. The company primarily explores for gold, silver, and antimony. Its principal asset is the 100% owned Stibnite gold project located in Valley County, Idaho. The company was formerly known as Midas Gold Corp. and changed its name to Perpetua Resources Corp. in February 2021. Perpetua Resources Corp. was incorporated in 2011 and is headquartered in Boise, Idaho.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 981.91K | 61.29K | 58.92K | 284.41K | 249.30K | 267.09K | 639.73K | 1.03M | 1.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -981.91K | -61.29K | -58.92K | -284.41K | -249.30K | -267.09K | -639.73K | -1.03M | -1.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.15K | 9.58M | 18.51M | 4.42M | 4.12M | 3.07M | 3.59M | 2.67M | 1.98M | 2.42M | 3.91M | 7.81M | 11.27M | 611.03K |
| Selling & Marketing | 31.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.82M | 9.58M | 18.51M | 4.42M | 4.12M | 3.07M | 3.59M | 2.67M | 1.98M | 2.42M | 3.91M | 7.81M | 11.27M | 611.03K |
| Other Expenses | -74.10K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.45M | 0.00 |
| Operating Expenses | -40.27M | 29.24M | 41.23M | 29.67M | 30.99M | 28.14M | 24.56M | 11.69M | 1.98M | 2.42M | 3.91M | 7.81M | 11.27M | 611.03K |
| Cost & Expenses | -40.27K | 29.30M | 41.29M | 29.96M | 31.24M | 28.41M | 25.20M | 12.72M | 1.98M | 2.42M | 3.91M | 7.81M | 11.27M | 611.03K |
| Interest Income | 442.94K | 485.47K | 58.31K | 277.82K | 548.04K | 636.72K | 293.55K | 215.08K | 23.15K | 56.57K | 84.63K | 197.72K | 276.46K | 22.83K |
| Interest Expense | 0.00 | 0.00 | 362.55K | 3.16M | 2.71M | 2.48M | 2.23M | 1.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 981.91K | 4.63M | 12.26M | 284.41K | 249.30K | 267.09K | 639.73K | 1.03M | 8.94K | 25.38K | 34.27K | 35.32K | 10.23K | 0.00 |
| EBITDA | -17.79M | -24.09M | -23.33M | -29.51M | -8.34M | -44.55M | -24.18M | -11.37M | -9.73M | -2.02M | -3.76M | -7.14M | -13.09M | -542.57K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 40.27K | -29.33M | 41.29M | 29.96M | 31.24M | -28.41M | -25.20M | -12.72M | -1.98M | -2.42M | -3.91M | -7.81M | -11.27M | -611.03K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -18.81M | -58.05M | -77.24M | -190.67M | 19.94M | -18.88M | 16.91M | -33.44M | 681.92K | 1.84M | 111.97K | 633.17K | -2.45M | 0.00 |
| Income Before Tax | -18.77M | -28.71M | -35.95M | -220.63M | -11.30M | -47.29M | -8.29M | -46.16M | -1.30M | -573.75K | -3.80M | -7.18M | -13.71M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -167.19K | 362.55K | 3.16M | 2.71M | 2.48M | 2.23M | 1.68M | -681.92K | -1.84M | -111.97K | -633.17K | -276.46K | 588.19K |
| Net Income | -18.77M | -28.71M | -35.95M | -220.63M | -11.30M | -47.29M | -8.29M | -46.16M | -1.30M | -573.75K | -3.80M | -7.18M | -13.44M | -588.19K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.30 | -0.46 | -0.66 | -6.45 | -0.44 | -2.18 | -0.45 | -2.65 | -0.08 | -0.04 | -0.31 | -0.64 | -1.59 | -0.15 |
| EPS Diluted | -0.30 | -0.46 | -0.66 | -6.45 | -0.44 | -2.18 | -0.45 | -2.65 | -0.08 | -0.04 | -0.31 | -0.64 | -1.59 | -0.15 |
| Weighted Avg Shares Out | 63.19M | 62.99M | 54.53M | 34.23M | 25.46M | 21.69M | 18.40M | 17.40M | 15.35M | 13.93M | 12.11M | 11.27M | 8.47M | 3.82M |
| Weighted Avg Shares Out (Dil) | 63.19M | 62.99M | 54.53M | 34.23M | 25.46M | 21.69M | 18.40M | 17.40M | 15.35M | 13.93M | 12.11M | 11.27M | 8.47M | 3.82M |
Perpetua Resources: I Worry About The Antimony Myself
Perpetua Resources wants to reopen Stibnite - not a bad idea on the face of it. There's gold and silver in them thar hills 'n' all after all.
5 Top Penny Stocks To Watch With News Before Next Week
Penny stocks to watch this week with news. The post 5 Top Penny Stocks To Watch With News Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
LFB Plasma Joins Plasma Protein Therapeutics Association (PPTA)
BOCA RATON, Fla.--(BUSINESS WIRE)--LFB Plasma, a US-based plasma collection company and subsidiary of the LFB Group, a leading European company providing plasma-derived products to healthcare professionals, announces joining the Plasma Protein Therapeutics Association (PPTA). LFB Plasma operates plasma collection centers...
Perpetua: Largest Independent Gold Project In The Country And Undervalued
The Corporation's principal mineral project is the Stibnite Gold Project, which contains several gold, silver, and antimony mineral deposits. If management is right, we would be talking about a gold project with a net present value of more than $1.2...
Perpetua Resources Corp. (PPTA) Upgraded to Buy: Here's Why
Perpetua Resources Corp. (PPTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Perpetua Resources Corp. (PPTA) Upgraded to Buy: What Does It Mean for the Stock?
Perpetua Resources Corp. (PPTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Best Penny Stocks To Buy For March According To Insiders
Insiders think these are penny stocks to buy. The post Best Penny Stocks To Buy For March According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Plasma Technologies Novel Plasma Fractionation Process Improves Yields, Purity of IgG
CHARLESTON, S.C.--(BUSINESS WIRE)--Plasma Technologies LLC (PlasmaTech), a plasma biologics technology company, announced that its novel human plasma fractionation process has been shown to achieve a yield of highly purified immunoglobulin G (IgG) in excess of 74% of the starting IgG...
Perpetua Resources to Present at Upcoming Conferences
BOISE, Idaho, Sept. 1, 2021 /PRNewswire/ - Perpetua Resources Corp. (Nasdaq: PPTA) (TSX: PPTA) ("Perpetua Resources" or the "Company") announced today that Laurel Sayer, President and CEO, will present at upcoming industry conferences.
Shortsighted Border Policy Puts Millions With Chronic Disease at Risk of Blood Plasma Shortages
WASHINGTON--(BUSINESS WIRE)--In addition to a detailed letter to the U.S. Department of Homeland Security (DHS) and U.S. Customs and Border Protection (CBP) raising serious concerns over a recent change in federal policy that threatens the U.S. supply of blood plasma...
Source: https://incomestatements.info
Category: Stock Reports